Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting

Xeris Pharmaceuticals ( (XERS) ) has issued an update.

On June 4, 2025, Xeris Biopharma Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made. Three individuals were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The stockholders also approved the compensation of the Company’s Named Executive Officers on a non-binding advisory basis.

The most recent analyst rating on (XERS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.

Spark’s Take on XERS Stock

According to Spark, TipRanks’ AI Analyst, XERS is a Neutral.

Xeris Pharmaceuticals demonstrates strong revenue growth and positive sentiment from recent earnings calls and corporate events. However, challenges with profitability, leverage, and valuation metrics moderate the overall score.

To see Spark’s full report on XERS stock, click here.

More about Xeris Pharmaceuticals

Xeris Biopharma Holdings, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing innovative therapies for patients with endocrine and metabolic diseases. The company is known for its proprietary technology platforms that enable the subcutaneous delivery of highly concentrated, ready-to-use, and room-temperature stable formulations of injectable and infusible drugs.

Average Trading Volume: 3,205,600

Technical Sentiment Signal: Buy

Current Market Cap: $808.8M

For an in-depth examination of XERS stock, go to TipRanks’ Stock Analysis page.